心血管威廉亚洲博彩公司

订阅

MedSci主页 / 所有栏目 / 心血管威廉亚洲博彩公司

血脂异常疾病检验诊断报告模式专家共识

2018-06-14 世界华人检验与病理医师协会 中华医学杂志.2018.98(22):1739-1742.

血脂异常疾病检验诊断报告模式

2015年初，中国国家卫生和计划生育委员会发布《中国居民营养与慢性病状况报告）显示，2012年中国成人血脂异常患病率达40.40%，由于血脂异常的主要危害是增加动脉粥样硬化性心血管疾病（ASCVD）的发病风险，所以，由此而导致的心脑血管疾病的发病率也逐年上升。 检验医学与血脂代谢相关的项目越来越多，越来越细化，涉及各个不同代谢环节并直接影响血脂异常的诊断、危险性分层以及血脂治疗和管理全过程。因此，

中文标题：

血脂异常疾病检验诊断报告模式专家共识

发布机构：

世界华人检验与病理医师协会

发布日期：

2018-06-14

简要介绍：

2015年初，中国国家卫生和计划生育委员会发布《中国居民营养与慢性病状况报告）显示，2012年中国成人血脂异常患病率达40.40%，由于血脂异常的主要危害是增加动脉粥样硬化性心血管疾病（ASCVD）的发病风险，所以，由此而导致的心脑血管疾病的发病率也逐年上升。 检验医学与血脂代谢相关的项目越来越多，越来越细化，涉及各个不同代谢环节并直接影响血脂异常的诊断、危险性分层以及血脂治疗和管理全过程。因此，系统的梳理血脂相关检验项目，分层分级逐步分析，对血脂异常的相关疾病，特别是对ASCVD的临床判断和预防具有十分重要的意义。

拓展威廉亚洲博彩公司 ：与血脂相关威廉亚洲博彩公司 ：

相关资料下载：
[AttachmentFileName(sort=100, fileName=血脂异常疾病检验诊断报告模式专家共识)] GetToolGuiderByIdResponse(projectId=1, id=a5fa71c0016051e6, title=血脂异常疾病检验诊断报告模式专家共识, enTitle=, guiderFrom=中华医学杂志.2018.98(22):1739-1742., authorId=null, author=, summary=2015年初，中国国家卫生和计划生育委员会发布《中国居民营养与慢性病状况报告）显示，2012年中国成人血脂异常患病率达40.40%，由于血脂异常的主要危害是增加动脉粥样硬化性心血管疾病（ASCVD）的发病风险，所以，由此而导致的心脑血管疾病的发病率也逐年上升。 检验医学与血脂代谢相关的项目越来越多，越来越细化，涉及各个不同代谢环节并直接影响血脂异常的诊断、危险性分层以及血脂治疗和管理全过程。因此，, cover=, journalId=null, articlesId=null, associationId=1671, associationName=世界华人检验与病理医师协会, associationIntro=, copyright=0, guiderPublishedTime=Thu Jun 14 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=<div>2015年初，中国国家卫生和计划生育委员会发布《中国居民营养与慢性病状况报告）显示，2012年中国成人血脂异常患病率达40.40%，由于血脂异常的主要危害是增加动脉粥样硬化性心血管疾病（ASCVD）的发病风险，所以，由此而导致的心脑血管疾病的发病率也逐年上升。 检验医学与血脂代谢相关的项目越来越多，越来越细化，涉及各个不同代谢环节并直接影响血脂异常的诊断、危险性分层以及血脂治疗和管理全过程。因此，系统的梳理血脂相关检验项目，分层分级逐步分析，对血脂异常的相关疾病，特别是对ASCVD的临床判断和预防具有十分重要的意义。</div> <div><br> </div>拓展威廉亚洲博彩公司 ：<strong>与<font color=red>血脂</font>相关威廉亚洲博彩公司 ：</strong><br><ul><li><a href="//www.nyrain.com/guideline/show_article.do?id=217591c00155a2bb" title="血脂康（胶囊）临床应用中国专家共识（2017修订版）" target=_blank>血脂康（胶囊）临床应用中国专家共识（2017修订版）</a></li> <li><a href="//www.nyrain.com/guideline/show_article.do?id=74a0a1c0015a49cd" title="2型糖尿病合并血脂异常的他汀类药物治疗专家共识（基层版）" target=_blank>2型糖尿病合并血脂异常的他汀类药物治疗专家共识（基层版）</a></li> <li><a href="//www.nyrain.com/guideline/show_article.do?id=b5a591c0015251ed" title="中国2型糖尿病合并血脂异常防治专家共识（2017年修订版）" target=_blank>中国2型糖尿病合并血脂异常防治专家共识（2017年修订版）</a></li> <li><a href="//www.nyrain.com/guideline/show_article.do?id=c135b1c00150a2f8" title="多廿烷醇治疗老年人血脂异常的临床应用专家共识" target=_blank>多廿烷醇治疗老年人血脂异常的临床应用专家共识</a></li> <li><a href="//www.nyrain.com/guideline/show_article.do?id=118da1c0015005d8" title="2017年AACE/ACE血脂异常管理与动脉粥样硬化疾病预防威廉亚洲博彩公司 简介" target=_blank>2017年AACE/ACE血脂异常管理与动脉粥样硬化疾病预防威廉亚洲博彩公司 简介</a></li> 更多信息请点击：<a href="//www.nyrain.com/guideline/list.do?q=%E8%A1%80%E8%84%82" target=_blank>有关血脂更多威廉亚洲博彩公司 </a></ul>, tagList=[TagDto(tagId=76487, tagName=血脂异常疾病), TagDto(tagId=56790, tagName=检验诊断), TagDto(tagId=76488, tagName=报告模式)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=69, categoryName=检验, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=7761, appHits=605, showAppHits=3, pcHits=5713, showPcHits=2234, likes=142, shares=27, comments=11, approvalStatus=1, publishedTime=Tue Jun 19 21:57:59 CST 2018, publishedTimeString=2018-06-14, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Tue Jun 19 21:57:59 CST 2018, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 04:21:10 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=血脂异常疾病检验诊断报告模式专家共识)])
血脂异常疾病检验诊断报告模式专家共识
下载请点击：
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=953701, encodeId=1142953e0100, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210203/b3b3dbb29fc34bdab94a8b8448c811ed/620edf7298d34ab499e182eefb2ea0bf.jpg, createdBy=a8cb5458412, createdName=xiuzhi, createdTime=Sun Apr 04 00:49:50 CST 2021, time=2021-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901244, encodeId=9f439012448c, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95765437425, createdName=ms5000001397452031, createdTime=Sun Nov 22 18:32:42 CST 2020, time=2020-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886259, encodeId=0c4888625912, content=好好学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64955306951, createdName=1487ba13m03暂无昵称, createdTime=Fri Sep 18 07:39:06 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325514, encodeId=df7832551467, content=好文献学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Wed Jun 20 06:47:09 CST 2018, time=2018-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325487, encodeId=d4be32548ebd, content=学习了受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Wed Jun 20 05:46:57 CST 2018, time=2018-06-20, status=1, ipAttribution=)]
    2021-04-04 xiuzhi

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=953701, encodeId=1142953e0100, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210203/b3b3dbb29fc34bdab94a8b8448c811ed/620edf7298d34ab499e182eefb2ea0bf.jpg, createdBy=a8cb5458412, createdName=xiuzhi, createdTime=Sun Apr 04 00:49:50 CST 2021, time=2021-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901244, encodeId=9f439012448c, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95765437425, createdName=ms5000001397452031, createdTime=Sun Nov 22 18:32:42 CST 2020, time=2020-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886259, encodeId=0c4888625912, content=好好学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64955306951, createdName=1487ba13m03暂无昵称, createdTime=Fri Sep 18 07:39:06 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325514, encodeId=df7832551467, content=好文献学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Wed Jun 20 06:47:09 CST 2018, time=2018-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325487, encodeId=d4be32548ebd, content=学习了受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Wed Jun 20 05:46:57 CST 2018, time=2018-06-20, status=1, ipAttribution=)]
    2020-11-22 ms5000001397452031

    谢谢

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=953701, encodeId=1142953e0100, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210203/b3b3dbb29fc34bdab94a8b8448c811ed/620edf7298d34ab499e182eefb2ea0bf.jpg, createdBy=a8cb5458412, createdName=xiuzhi, createdTime=Sun Apr 04 00:49:50 CST 2021, time=2021-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901244, encodeId=9f439012448c, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95765437425, createdName=ms5000001397452031, createdTime=Sun Nov 22 18:32:42 CST 2020, time=2020-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886259, encodeId=0c4888625912, content=好好学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64955306951, createdName=1487ba13m03暂无昵称, createdTime=Fri Sep 18 07:39:06 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325514, encodeId=df7832551467, content=好文献学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Wed Jun 20 06:47:09 CST 2018, time=2018-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325487, encodeId=d4be32548ebd, content=学习了受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Wed Jun 20 05:46:57 CST 2018, time=2018-06-20, status=1, ipAttribution=)]
    2020-09-18 1487ba13m03暂无昵称

    好好学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=953701, encodeId=1142953e0100, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210203/b3b3dbb29fc34bdab94a8b8448c811ed/620edf7298d34ab499e182eefb2ea0bf.jpg, createdBy=a8cb5458412, createdName=xiuzhi, createdTime=Sun Apr 04 00:49:50 CST 2021, time=2021-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901244, encodeId=9f439012448c, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95765437425, createdName=ms5000001397452031, createdTime=Sun Nov 22 18:32:42 CST 2020, time=2020-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886259, encodeId=0c4888625912, content=好好学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64955306951, createdName=1487ba13m03暂无昵称, createdTime=Fri Sep 18 07:39:06 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325514, encodeId=df7832551467, content=好文献学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Wed Jun 20 06:47:09 CST 2018, time=2018-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325487, encodeId=d4be32548ebd, content=学习了受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Wed Jun 20 05:46:57 CST 2018, time=2018-06-20, status=1, ipAttribution=)]
    2018-06-20 张新亮1853311252142e2fm

    好文献学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=953701, encodeId=1142953e0100, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210203/b3b3dbb29fc34bdab94a8b8448c811ed/620edf7298d34ab499e182eefb2ea0bf.jpg, createdBy=a8cb5458412, createdName=xiuzhi, createdTime=Sun Apr 04 00:49:50 CST 2021, time=2021-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901244, encodeId=9f439012448c, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95765437425, createdName=ms5000001397452031, createdTime=Sun Nov 22 18:32:42 CST 2020, time=2020-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886259, encodeId=0c4888625912, content=好好学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64955306951, createdName=1487ba13m03暂无昵称, createdTime=Fri Sep 18 07:39:06 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325514, encodeId=df7832551467, content=好文献学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Wed Jun 20 06:47:09 CST 2018, time=2018-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325487, encodeId=d4be32548ebd, content=学习了受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Wed Jun 20 05:46:57 CST 2018, time=2018-06-20, status=1, ipAttribution=)]
    2018-06-20 131****1460

    学习了受益匪浅

    0